Cancer is projected to claim 618,000 lives in the U.S. in 2025, according to the American Cancer Society. Despite advances in treatment, most deaths occur from cancers that don’t currently have guideline-recommended screening tests.
Today, the CDC recommends screening for only four cancers — breast, cervical, colorectal, and lung — leaving two-thirds of cancers undetected until symptoms appear. Once cancers reach these later stages, treatments are less effective and survival rates drop significantly.
That gap is where multi-cancer early detection (MCED) could change the landscape. MCED is a blood-based screening test designed to identify dozens of cancer types simultaneously, detecting disease much earlier when treatment has the best chance of success.
As explained by Dr. Tom Beer, VP and Chief Medical Officer for MCED at Exact Sciences, “earlier detection through screening saves lives — and that’s really our best hope in the fight against cancer.” Unlike traditional screening methods, which target individual cancer types, MCED’s simplicity — a single blood draw — makes it highly scalable and accessible.
Experts believe MCED could extend early detection to most cancers people are at risk for, potentially transforming national screening strategies. However, for healthcare leaders, this innovation will require integration into EHR systems and thoughtful consideration of clinical workflows, data sharing, and patient communication as adoption grows.
The promise of MCED represents a pivotal step toward broad, proactive cancer screening — one that could shift healthcare from reactive treatment to true early intervention.
Resource: A new era in cancer screening: What leaders should know about multi-cancer early detection